• xpj(中国)旗舰厅

    Welcome to HitGen
    CN EN

    Capabilities & Services

    Enabling Innovative Drug Discovery with Advanced Technologies

    • DEL for
      DEL for
    • DNA-encoded Library
      DNA-encoded Library
    • Fragment-based Drug Discovery
      FBDD/SBDD
    • Chemistry
      Chemistry
    • Bioscience
      Bioscience
    • Computational Sciences and Informatics
      Computational Sciences and Informatics
    • Structural Biology
      Structural Biology
    • Pre-clinical Studies
      Pre-clinical Studies
    • Clinical Development
      Clinical Development

    Therapeutic Areas

    Integrated One-stop Drug Discovery Platform   Accelerating Project with High Efficiency

    • Oncology and Immuno-oncology
      Oncology and Immuno-oncology
    • Inflammatory and Autoimmune Diseases
      Inflammatory and Autoimmune Diseases
    • Ophthalmology
      Ophthalmology
    • Infectious Diseases
      Infectious Diseases
    • Metabolic Diseases
      Metabolic Diseases
    • Cardiovascular Diseases
      Cardiovascular Diseases
    HitGen Inc. is a rapidly developing biotech company
    The discovery and development of novel medicines and agrochemicals
    >1.2 Trillion

    DNA encoded compounds

    >6,000

    novel drug/target complex structures for FBDD/SBDD

    About Us

    HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.


    For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.110962.com.

    For media inquiries: media@110962.com

    For investor inquiries: investors@110962.com  

    For business development: bd@110962.com  


    Read More

    Collaboration Partners

    Latest News

    • 24 April 2024

      Infographic | HitGen FY2023&2024Q1 Report

      Infographic | HitGen FY2023&2024Q1 Report
      + Read More
    • 08 April 2024

      Vernalis announces a drug discovery collaboration with C4X Discovery in inflammatory disease

      Vernalis (R&D) Limited (“Vernalis”), a wholly owned subsidiary of HitGen Inc., and C4X Discovery (“C4XD”) are pleased to announce a collaboration to identify modulators of an undisclosed high-value target involved in inflammatory disease.
      + Read More
    • 26 March 2024

      HitGen Partners with LabCentral / BioLabs / MBC BioLabs to Accelerate Biotechnology Discovery

      [San Francisco, CA – March 25, 2024] – LabCentral, a launchpad for high-potential life science and biotech start-ups, BioLabs, an international membership-based network of shared lab and office facilities, and MBC BioLabs, premier providers of co-working laboratory space, announced a partnership with HitGen, a global leader in the design, synthesis, and screening of DNA-encoded chemical libraries (DELs).
      + Read More
    Investors

    Latest Announcements,
    Financial News and Stock Information

    Read More

    Thanks for reading!

    For more details on how we can advance your innovative drug discovery projects
    验证码
    By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

    We use cookies to provide a better web experience.
    By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information